Covid-19
2022 Guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19.
1 Jul, 2022 | 11:50h | UTCRelated:
Two new studies show no benefit of Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19.
1 Jul, 2022 | 11:49h | UTCCommentaries:
Antithrombotic Prophylaxis No Help in Outpatients With COVID — Two trials show no differences between patients who received enoxaparin vs standard of care – MedPage Today (free registration required)
Commentary on Twitter (thread – click for more)
Early in the pandemic we wondered whether antithrombotic therapy in outpatients with #COVID19 would prevent #thrombosis ❓
Several trials were started globally and the ACTIV-4B trial was previously reported⬇️ https://t.co/Q15WcZwDIA
Now, we publish the OVID and ETHIC trials?
— The Lancet Haematology (@TheLancetHaem) June 30, 2022
Accuracy of rapid antigen vs. RT-PCR testing for SARS-CoV-2 infection in college athletes during prevalence of the Omicron variant.
1 Jul, 2022 | 11:39h | UTC
Commentary on Twitter
In this case series of college athletes returning to campus during Omicron, rapid antigen tests were 63% sensitive, >99% specific for #COVID19, similar to previous strains and less well in detecting asymptomatic #SARSCoV2. @helixcardinal @stanford_ortho https://t.co/SBPr6NQ9Na
— JAMA Network Open (@JAMANetworkOpen) June 15, 2022
Cohort Study: Effectiveness of Pfizer, Moderna, and AstraZeneca vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting.
1 Jul, 2022 | 11:37h | UTC
Commentary on Twitter
? Read our latest research article comparing the effectiveness of three #COVID vaccines against severe COVID outcomes. ▶️ https://t.co/uaQNgnDrrV#BMJMedicine #MedTwitter #openaccess pic.twitter.com/4oeG5d0j80
— BMJMedicine (@BMJMedicine) June 16, 2022
Cohort Study: Pfizer vaccine effectiveness against omicron in children 5 to 11 years of age.
30 Jun, 2022 | 11:21h | UTC
Wearable activity trackers plus AI might be used to pick up presymptomatic COVID-19.
30 Jun, 2022 | 11:18h | UTCNews Release: Wearable activity trackers + AI might be used to pick up presymptomatic COVID-19 – BMJ Newsroom
Systematic Review: Long distance airborne transmission of SARS-CoV-2.
30 Jun, 2022 | 11:17h | UTCLong distance airborne transmission of SARS-CoV-2: rapid systematic review – The BMJ
Editorial: Airborne SARS-CoV-2 – The BMJ
News Release: New review of evidence highlights importance of adequate ventilation to prevent spread of covid-19 in indoor settings – BMJ
RCT: A 2-week interruption in methotrexate treatment doubles the antibody response to a COVID-19 booster vaccine.
29 Jun, 2022 | 12:10h | UTCNews Releases:
Interrupting immune-suppressing treatment can boost COVID vaccine response – Imperial College London
Commentaries:
Commentary on Twitter
NEW Research—2-week interruption of methotrexate treatment for people w/ immune-mediated inflammatory diseases = enhanced boosting of antibody responses after #COVID19 vaccination
From Prof Abhishek Abhishek & colleagues https://t.co/y14pUEaB5X pic.twitter.com/pLvaXjJzoz
— The Lancet Respiratory Medicine (@LancetRespirMed) June 28, 2022
Perspective | Fast-evolving COVID variants complicate vaccine updates.
29 Jun, 2022 | 12:01h | UTCFast-evolving COVID variants complicate vaccine updates – Nature
Retrospective Cohort Study: Key characteristics impacting survival of COVID-19 extracorporeal membrane oxygenation.
29 Jun, 2022 | 11:54h | UTC
An analysis of SARS-CoV-2 vaccine reactogenicity: variation by type, dose, and history, severity, and recency of prior SARS-CoV-2 infection.
29 Jun, 2022 | 11:52h | UTC
Long COVID symptoms in SARS-CoV-2-positive children aged 0–14 years and matched controls in Denmark: a national, cross-sectional study.
28 Jun, 2022 | 11:16h | UTCNews Release: Largest study reports long COVID symptoms in children up to age 14 – Lancet
Commentaries:
Difficult questions about long COVID in children – The Lancet Child & Adolescent Health
Kids do get long COVID, but it seems uncommon, data reveal – CIDRAP
Cardiovascular damage in COVID-19: What we know two years later.
28 Jun, 2022 | 11:11h | UTCCardiovascular Damage in COVID-19: What We Know Two Years Later – Current Cardiology Reports
Cohort Study: Association of receipt of the fourth BNT162b2 dose with omicron infection and COVID-19 hospitalizations among residents of long-term care facilities.
28 Jun, 2022 | 11:08h | UTCCommentary: Fourth Dose of BNT162b2 Prevents Severe COVID-19 in Nursing Home Residents – HealthDay
Commentary on Twitter
Cohort study found that vaccination with a fourth BNT162b2 dose vs 3 doses given 4 months or earlier, was associated with lower risk of hospitalizations by 64-67% and deaths by 72%, among residents of long-term care facilities during massive Omicron surge. https://t.co/LTZ4umgSDh
— JAMA Internal Medicine (@JAMAInternalMed) June 23, 2022
2022 AHA/ACC key data elements and definitions for cardiovascular and noncardiovascular complications of COVID-19.
27 Jun, 2022 | 12:01h | UTCNews Release: New ACC/AHA Data Standards Address CV, Noncardiovascular Complications of COVID-19 – American College of Cardiology
Epidemiology of myocarditis and pericarditis following mRNA vaccination by vaccine product, schedule, and interdose interval among adolescents and adults in Ontario, Canada.
27 Jun, 2022 | 11:51h | UTCCommentary: Young Men’s Myocarditis Risk 5 Times Higher With Moderna vs Pfizer Vax — But Canadian study finds that 8-week interval before second dose attenuates some of the risk – MedPage Today (free registration required)
[Press Release – not published yet]: RCT: Sanofi-GSK report its vaccine targeted against ancestral and Beta strains had an overall efficacy of 72% against the Omicron variant.
27 Jun, 2022 | 11:52h | UTCPress Release: Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine – Sanofi
Commentaries: Bivalent COVID Vax Gets Phase III Win Against Omicron, Companies Say — Sanofi, GSK boast of 72% efficacy against Omicron variant – MedPage Today (free registration required)
Use of pragmatic and explanatory trial designs in acute care research: lessons from COVID-19.
27 Jun, 2022 | 11:49h | UTC
Commentary on Twitter
NEW Personal View—Use of pragmatic and explanatory trial designs in acute care research: lessons from #COVID19
From Jonathan Casey & colleagues https://t.co/3vJs5j6Q1Q pic.twitter.com/hEUFYxNKRf
— The Lancet Respiratory Medicine (@LancetRespirMed) June 14, 2022
Perspective | What Omicron’s BA.4 and BA.5 variants mean for the pandemic.
27 Jun, 2022 | 11:48h | UTCWhat Omicron’s BA.4 and BA.5 variants mean for the pandemic – Nature
Vaccinations may have prevented almost 20 million COVID-19 deaths worldwide.
27 Jun, 2022 | 11:46h | UTCNews Release: Vaccinations may have prevented almost 20 million COVID-19 deaths worldwide – Imperial College London
Original Study: Global impact of the first year of COVID-19 vaccination: a mathematical modelling study – The Lancet Infectious Diseases
Commentaries:
Covid-19 vaccines prevented nearly 20 million deaths in a year, study estimates – STAT
COVID-19 vaccines saved an estimated 20 million lives in 1 year – CIDRAP
Commentary on Twitter (thread – click for more)
? @TheLancetInfDis
In the 1st year of Covid vaccinations, ~20 million deaths were prevented worldwide (data from 185 countries)
Another ~600,000 lives would have been saved if the @WHO 40% target been achievedhttps://t.co/BWig83xlnN @azraghani @imperialcollege @MRC_Outbreak pic.twitter.com/lF8biBJIlK— Eric Topol (@EricTopol) June 23, 2022
New COVID drugs face delays as trials grow more difficult.
24 Jun, 2022 | 11:47h | UTCNew COVID drugs face delays as trials grow more difficult – Nature
Perspective | Four areas of health innovation boosted by the pandemic.
24 Jun, 2022 | 11:36h | UTCFour areas of health innovation boosted by the pandemic – Nature Medicine
Commentary on Twitter
Leading researchers speak with @NatureMedicine about how the COVID-19 pandemic has spurred research on wearables, genomic surveillance, behavioral interventions and drug discovery. https://t.co/k3Svb0xBVB
— Nature Portfolio (@NaturePortfolio) June 17, 2022
Cohort Study: COVID-19 trajectories among 57 million adults in England.
24 Jun, 2022 | 11:34h | UTCNews Release: Most comprehensive analysis of COVID-19 data reveals previously unattributed deaths – Health Data Research UK
Commentary from one of the authors on Twitter (thread – click for more)
? COVID-19 trajectories among 57 million adults in England: a cohort study using electronic health records
Proud to share this work with @johanhilge @SpirosDenaxas @BHFDataScience @HDR_UK + team in @LancetDigitalHhttps://t.co/DY96ClN0c3
?
— Chris Tomlinson (@tomlincr) June 9, 2022
Ivermectin for COVID-19 Cochrane review update: 11 trials and no evidence of benefit shown.
23 Jun, 2022 | 10:38h | UTCNews Release: Ivermectin for COVID-19 review update: 11 trials and no evidence of benefit shown – Liverpool School of Tropical Medicine
Original Article: Ivermectin for preventing and treating COVID‐19 – Cochrane Library
Summary: Ivermectin for preventing and treating COVID-19 – Cochrane Library
Systematic Review: SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19.
23 Jun, 2022 | 10:37h | UTCSARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 – Cochrane Library